Although only select CAR-NK therapies for hematologic malignancies were highlighted in this review, it is important to note there are several other CAR-NKs targeting various TAAs in the preclinical and clinical pipeline, including but not limited to CAR-NKs for use in refractory B cell lymphoma (CD22-CAR-NK, CD19-CAR-NK, CD22/CD19-CAR-NK), diffuse large B cell lymphoma (CD19-t-haNK), T cell ALL (CD7-CAR-NK) [87] and relapsed and refractory multiple myeloma (BCMA-CAR-NK) (NCT03940833) (Table 1). This evidence concerns the gene CD19 and plasma cell myeloma.